HEALTH-RELATED QUALITY OF LIFE AND HEALTH STATE UTILITY VALUES AMONG REAL-WORLD PATIENTS WITH ACUTE MYELOID LEUKEMIA IN TAIWAN
Author(s)
Thi Thuy Dung Nguyen, MS1, Yi-Hsin Chang, MS2, Huang-tz Ou, PhD3, Ying-Li Chen, MS4.
1PhD student, National Cheng Kung University, Tainan, Taiwan, 2National Cheng Kung University, Tainan, Taiwan, 3Institute of Clinical Pharmacy and Pharmaceutical Science, National Cheng Kung University, Tainan, Taiwan, 4Daiichi Sankyo Taiwan Ltd., Taipei, Taiwan.
1PhD student, National Cheng Kung University, Tainan, Taiwan, 2National Cheng Kung University, Tainan, Taiwan, 3Institute of Clinical Pharmacy and Pharmaceutical Science, National Cheng Kung University, Tainan, Taiwan, 4Daiichi Sankyo Taiwan Ltd., Taipei, Taiwan.
OBJECTIVES: Acute myeloid leukemia (AML), an aggressive hematological malignancy, substantially impairs health-related quality of life (HRQoL), yet Taiwan-specific health-state utility values (HSUVs) across clinically relevant AML states remain scarce. We assessed HRQoL and HSUVs among Taiwanese patients with AML across key disease and treatment states.
METHODS: This was a multicenter cross-sectional study, recruiting adults with AML across 8 health states: induction, consolidation, maintenance, complete remission (CR), relapse/refractory, pre-hematopoietic stem cell transplantation (HSCT), HSCT treatment, and post-HSCT. Participants completed a self-administered questionnaire including demographics, the Traditional Chinese EQ-5D-5L, and the EORTC QLQ-C30. In EORTC QLQ-C30, higher scores on functional scales indicate better functioning, whereas higher scores on symptom scales indicate greater symptom burden. HSUVs were derived using the Taiwan EQ-5D-5L value set. Descriptive analyses were performed overall and by health state.
RESULTS: Between April and December 2025, 101 responses from 98 patients were analyzed. The mean age was 52.38 years, and 51.49% were female. On the EORTC QLQ-C30, social functioning showed the greatest impairment (mean [SD], 73.10 [29.15]), while fatigue was the most prominent symptom (29.92 [24.88]). The overall mean HSUV was 0.85 (SD 0.25; range -0.67 to 1.00). HSUVs were lowest during induction (0.60 [0.42]), improved during consolidation (0.91 [0.08]) and maintenance (0.97 [0.06]), and remained high in CR (0.97 [0.06]). Patients with relapsed/refractory disease had lower HSUVs (0.85 [0.15]). Around HSCT, HSUV declined from 0.87 [0.19] pre-HSCT to 0.74 [0.27] during HSCT, then improved to 0.90 [0.15] post-HSCT.
CONCLUSIONS: Real-world HRQoL and HSUVs varied considerably across AML health states in Taiwan, with the greatest decrement during induction and HSCT. These findings provide locally relevant utility estimates across disease and treatment states, as well as symptom burden data, that may inform healthcare decision-making.
METHODS: This was a multicenter cross-sectional study, recruiting adults with AML across 8 health states: induction, consolidation, maintenance, complete remission (CR), relapse/refractory, pre-hematopoietic stem cell transplantation (HSCT), HSCT treatment, and post-HSCT. Participants completed a self-administered questionnaire including demographics, the Traditional Chinese EQ-5D-5L, and the EORTC QLQ-C30. In EORTC QLQ-C30, higher scores on functional scales indicate better functioning, whereas higher scores on symptom scales indicate greater symptom burden. HSUVs were derived using the Taiwan EQ-5D-5L value set. Descriptive analyses were performed overall and by health state.
RESULTS: Between April and December 2025, 101 responses from 98 patients were analyzed. The mean age was 52.38 years, and 51.49% were female. On the EORTC QLQ-C30, social functioning showed the greatest impairment (mean [SD], 73.10 [29.15]), while fatigue was the most prominent symptom (29.92 [24.88]). The overall mean HSUV was 0.85 (SD 0.25; range -0.67 to 1.00). HSUVs were lowest during induction (0.60 [0.42]), improved during consolidation (0.91 [0.08]) and maintenance (0.97 [0.06]), and remained high in CR (0.97 [0.06]). Patients with relapsed/refractory disease had lower HSUVs (0.85 [0.15]). Around HSCT, HSUV declined from 0.87 [0.19] pre-HSCT to 0.74 [0.27] during HSCT, then improved to 0.90 [0.15] post-HSCT.
CONCLUSIONS: Real-world HRQoL and HSUVs varied considerably across AML health states in Taiwan, with the greatest decrement during induction and HSCT. These findings provide locally relevant utility estimates across disease and treatment states, as well as symptom burden data, that may inform healthcare decision-making.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
PCR6
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology